Navigation Links
Possible genetic predictor for response to lithium augmentation in depressed patients
Date:12/6/2007

Philadelphia, PA, December 6, 2007 As in most fields of medicine, psychiatry researchers are working to identify specific types of patients, through their individual genetic variations, that may better benefit from particular drugs or combinations of drugs than other patients. A new study, published in Biological Psychiatrys December 1st issue, investigated whether depressed patients with a particular genetic variation would better respond to the addition of lithium to their treatment regimen, as opposed to an antidepressant-only treatment.

Adli and colleagues recruited acutely depressed patients who were unresponsive to an antidepressant-only treatment, and augmented their therapy with lithium, the most common medication used to treat bipolar disorder. They then genotyped these patients for variations in the GSK3B gene. This gene codes for the enzyme glycogen synthase kinase 3-beta, which is inhibited by lithium. Mazda Adli, M.D., corresponding author on the project, explains their findings: [We] found that antidepressant non-responders with depression show a significantly better response to a subsequent lithium augmentation if they carry at least one C-allele as opposed those patients carrying two T-alleles, which is in line with the previous findings regarding this genetic polymorphism. In other words, patients who carried a specific genetic variation, the C-allele, were more likely to get better with the addition of lithium to their treatment than patients with other variations of the GSK3B gene.

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments, Over the past several years, preclinical studies have suggested that GSK3-beta was a key molecular switch related to the clinical effectiveness of lithium. This hypothesis is supported by this report from Adli et al. They find that variation in the GSK3-beta gene is related to lithium response in patients, further implicating GSK3-beta as a potential target for antidepressant treatment. Dr. Adli adds, If replicable, the findings of this study could be an important step towards an individually tailored antidepressive treatment plan for patients with depression as well as for the identification of possible new drug targets.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Fairbank Farms Voluntarily Recalls 85% Ground Round Beef Patties Sold Fresh from Shaws Due to Possible Health Risk
2. M.D. Anderson-led team reports possible key to autoimmune disease
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Possible safer target for anti-clotting drugs found
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. Why it is impossible for some to just say no
7. Saving Millions of Childrens Lives Is Possible
8. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
9. Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
10. Help for California Fire Evacuees Possible Through Partnership for Prescription Assistance
11. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive ... now meet with Dr. Joseph Bedich for a consultation, with or without a referral. ... oral health and functionality. , Dr. Bedich offers a variety of cosmetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. ... of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate ... in his field by attending numerous CE courses each year. His recent course, ...
(Date:5/24/2017)... Brentwood, TN (PRWEB) , ... May 24, 2017 ... ... announced the addition of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first ... and security of every IT system, from the datacenter to the cloud to ...
(Date:5/24/2017)... ... 2017 , ... Rob Lowe is a sought after actor, and also serves ... the public important topics from all aspects of life, and a new segment is ... feet and ankles. , Podiatry is essential to people’s overall well-being, and if viewers ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: